Patten S B, Williams J V, Mitton C
University of Calgary, Department of Community Health Sciences, Calgary, Alberta.
Chronic Dis Can. 2008;28(4):155-62.
Costing studies are central to health policy decisions. Available costing estimates for mood and anxiety disorders in Canada may, however, be out of date. In this study, we estimated a set of direct health care costs using data collected in a provincial telephone survey of mood and anxiety disorders in Alberta. The survey used random digit dialing to reach a sample of 3394 household residents aged 18 to 64. A telephone interview included items assessing costs without reference to whether these were incurred by the respondent, government or a health plan. The survey interview also included the Mini Neuropsychiatric Diagnostic Interview (MINI). Costs for antidepressant medications appear to have increased since the last available estimates were published. Surprisingly, most medication costs for antidepressants were incurred by respondents without an identified disorder. Also, an unexpectedly large proportion of medication costs were for psychotropic medications other than antidepressants and anxiolytic-sedative-hypnotics. These results suggest that major changes have occurred in the costs associated with antidepressant treatment. Available cost-of-illness data may be outdated, and some assumptions made by previous studies may now be invalid.
成本核算研究对于卫生政策决策至关重要。然而,加拿大现有的情绪和焦虑症成本估算可能已经过时。在本研究中,我们利用在艾伯塔省进行的一项关于情绪和焦虑症的省级电话调查所收集的数据,估算了一系列直接医疗保健成本。该调查使用随机数字拨号法,选取了3394名年龄在18至64岁的家庭居民作为样本。电话访谈包括评估成本的项目,且不涉及这些成本是由受访者、政府还是医疗计划产生的。调查访谈还包括迷你神经精神诊断访谈(MINI)。自上次公布现有估算以来,抗抑郁药物的成本似乎有所增加。令人惊讶的是,大多数抗抑郁药物成本是由未确诊疾病的受访者产生的。此外,药物成本中用于抗抑郁药物和抗焦虑 - 镇静 - 催眠药物以外的精神药物的比例出乎意料地高。这些结果表明,与抗抑郁治疗相关的成本发生了重大变化。现有的疾病成本数据可能过时,并且先前研究做出的一些假设现在可能无效。